SCHEMBL4412804

SCHEMBL4412804

Cc1cc(-c2nc(COC3CCN(C(=O)OC(C)(C)C)CC3)no2)n(C)n1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 10/20 0.49
CPT1A P50416 2/20 0.42
CPT2 P23786 1/20 0.42
CETP P11597 2/20 0.38
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
TBK1 Q9UHD2 1/20 0.37
PIK3CD O00329 1/20 0.36
CACNB4 O00305 1/20 0.36
CACNA1A O00555 1/20 0.36
CACNA1G O43497 1/20 0.36
CACNG3 O60359 1/20 0.36
CACNA1F O60840 1/20 0.36
CACNA1H O95180 1/20 0.36
CACNB3 P54284 1/20 0.36
CACNA2D1 P54289 1/20 0.36
CACNG7 P62955 1/20 0.36
CACNA1B Q00975 1/20 0.36
CACNA1D Q01668 1/20 0.36
CACNB1 Q02641 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4416101 0.85 GPR119 (0.55) GPR119CETPPRMT5WDR77
SCHEMBL4427219 0.84 GPR119 (0.52) GPR119CPT1ACETPPRMT5WDR77
SCHEMBL4416551 0.84 GPR119 (0.49) GPR119CETPPRMT5WDR77PIK3CD
SCHEMBL4416069 0.83 GPR119 (0.53) GPR119PRMT5WDR77PIK3CD
SCHEMBL12548315 0.81 GPR119 (0.57) GPR119CETPPRMT5WDR77
SCHEMBL4415836 0.81 GPR119 (0.52) GPR119CETPPRMT5WDR77
SCHEMBL4414258 0.80 GPR119 (0.51) GPR119CETPPRMT5WDR77
SCHEMBL4418527 0.80 GPR119 (0.58) GPR119CETPPRMT5WDR77
SCHEMBL4415488 0.80 GPR119 (0.49) GPR119CETPPRMT5WDR77
SCHEMBL4419641 0.80 GPR119 (0.54) GPR119CETPPRMT5WDR77TBK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
US-20090325924-A1 GPCR Agonists PROSIDION LIMITED (GB) 2009-12-31 US disclosed
WO-2007003960-A1 GPCR AGONISTS PROSIDION LIMITED (GB) 2007-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325924-A1 GPCR Agonists GPR119, GCGR, GPR27 GPR119 1/4885CPT1A 631/4885CPT2 1381/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.